Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use or reduce dose and frequency. Hemodialysis: Not recommended.
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence, neonatal withdrawal syndrome, and reduced fetal growth. Acetaminophen component: no known teratogenic risk at therapeutic doses.
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
Hydrocodone/acetaminophen carries a boxed warning for addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; and hepatotoxicity (acetaminophen). Avoid in patients with severe respiratory depression, acute or severe bronchial asthma, GI obstruction, or known acetaminophen hypersensitivity. Maximum acetaminophen dose from all sources should not exceed 4 g/day (3 g/day in at-risk patients). Use with caution in elderly, cachectic, or debilitated patients due to increased risk of respiratory depression. CYP3A4 inducers (e.g., rifampin) may reduce hydrocodone efficacy; CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. Do not combine with other CNS depressants without dose adjustment. Monitor for signs of opioid-induced constipation; prescribe a bowel regimen. Prescribe immediate-release formulations only for acute pain (generally ≤3 days). Avoid combining with MAOIs or within 14 days of MAOI use.
No interactions on record
No interactions on record
OXYCODONE AND ASPIRIN (HALF-STRENGTH) and HYDROCODONE BITARTRATE AND ACETAMINOPHEN are distinct pharmacological agents. OXYCODONE AND ASPIRIN (HALF-STRENGTH) belongs to the Opioid Agonist class and is primarily used for Moderate to moderately severe pain (when combination therapy is appropriate)Off-label: acute pain, chronic pain. HYDROCODONE BITARTRATE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE AND ASPIRIN (HALF-STRENGTH) carries a safety status of Category D/X, whereas HYDROCODONE BITARTRATE AND ACETAMINOPHEN safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Hydrocodone: primarily CYP3A4 and CYP2D6 to hydromorphone (active). Acetaminophen: primarily glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation to NAPQI (toxic).
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
Hydrocodone: ~20-50% bound to albumin and other proteins. Acetaminophen: 10-25% bound to albumin.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Acetaminophen: 0.75-1.0 L/kg (primarily total body water).
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
Oral: Hydrocodone ~70-80% (first-pass metabolism). Acetaminophen ~60-90% (product dependent).
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce total daily dose by 50% or extend dosing interval. Child-Pugh C: Avoid use.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
Not recommended for children <18 years due to safety concerns. For postoperative tonsillectomy/adenoidectomy: contraindicated.
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/325 mg acetaminophen) and titrate slowly; monitor for CNS depression and constipation. Avoid in renal impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen overdose.
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Respiratory depression, drug dependence, abuse potential, risks with CNS depressants, elderly/debilitated patients, hepatic impairment, renal impairment, severe hypotension, head injury, seizures, use in pregnancy, use in breastfeeding, adrenal insufficiency, anaphylaxis, withdrawal, and driving impairment.
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Significant respiratory depression, acute or severe bronchial asthma, GI obstruction (including paralytic ileus), hypersensitivity to hydrocodone or acetaminophen, severe hepatic impairment, and known or suspected gastrointestinal obstruction.
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
Avoid alcohol consumption due to increased risk of hepatotoxicity and additive CNS depression. Grapefruit juice may inhibit CYP3A4 and potentially increase hydrocodone levels; consider avoiding or limiting intake. No significant food restrictions otherwise; may take with or without food. Maintain adequate hydration to prevent constipation.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Hydrocodone is excreted into human breast milk, with an M/P ratio approximately 2.5. Postpartum use may lead to infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Acetaminophen is excreted in low levels. Use is generally avoided due to risks; if used, monitor infant for drowsiness and feeding difficulties.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
No dosing adjustment recommended specifically for pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may result in lower serum concentrations; however, due to fetal risks, use the lowest effective dose for the shortest duration. Avoid use in third trimester unless necessary; monitor for neonatal withdrawal.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and any products containing acetaminophen (e.g., Tylenol, cold medicines) to prevent liver damage.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store in a secure place away from children and pets; dispose of unused medication via a drug take-back program.,Contact your doctor immediately if you experience shallow breathing, difficulty waking, confusion, or signs of allergic reaction.,Do not stop abruptly; withdrawal symptoms include anxiety, sweating, diarrhea, and muscle aches.,Inform all healthcare providers that you are taking this medication.,Use exactly as directed; misuse can lead to addiction, overdose, or death.